drugset / Trial / NCT03855917
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
Timeline
- Start
- 2020-02-11
- Primary completion
- 2026-02
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glecaprevir/pibrentasvir | Unknown | 120 mg | — |
| Subject | Glecaprevir/pibrentasvir | Unknown | 300 mg | — |
| Subject | Sofosbuvir | Small molecule | 400 mg | — |